Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer.

Angell HK, Lee J, Kim KM, Kim K, Kim ST, Park SH, Kang WK, Sharpe A, Ogden J, Davenport A, Hodgson DR, Barrett JC, Kilgour E.

Oncoimmunology. 2018 Dec 10;8(2):e1544442. doi: 10.1080/2162402X.2018.1544442. eCollection 2019.

2.

Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the 'U' out of 'CUP'.

Conway AM, Mitchell C, Kilgour E, Brady G, Dive C, Cook N.

Br J Cancer. 2019 Jan;120(2):141-153. doi: 10.1038/s41416-018-0332-2. Epub 2018 Dec 23. Review.

3.

Will liquid biopsies improve outcomes for patients with small-cell lung cancer?

Blackhall F, Frese KK, Simpson K, Kilgour E, Brady G, Dive C.

Lancet Oncol. 2018 Sep;19(9):e470-e481. doi: 10.1016/S1470-2045(18)30455-8. Review.

PMID:
30191851
4.

Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).

Carvajal RD, Piperno-Neumann S, Kapiteijn E, Chapman PB, Frank S, Joshua AM, Piulats JM, Wolter P, Cocquyt V, Chmielowski B, Evans TRJ, Gastaud L, Linette G, Berking C, Schachter J, Rodrigues MJ, Shoushtari AN, Clemett D, Ghiorghiu D, Mariani G, Spratt S, Lovick S, Barker P, Kilgour E, Lai Z, Schwartz GK, Nathan P.

J Clin Oncol. 2018 Apr 20;36(12):1232-1239. doi: 10.1200/JCO.2017.74.1090. Epub 2018 Mar 12. Erratum in: J Clin Oncol. 2018 Dec 10;36(35):3528.

PMID:
29528792
5.

Correlation between MEK signature and Ras gene alteration in advanced gastric cancer.

Ahn S, Brant R, Sharpe A, Dry JR, Hodgson DR, Kilgour E, Kim K, Kim ST, Park SH, Kang WK, Kim KM, Lee J.

Oncotarget. 2017 May 23;8(64):107492-107499. doi: 10.18632/oncotarget.18182. eCollection 2017 Dec 8.

6.

A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification.

Van Cutsem E, Bang YJ, Mansoor W, Petty RD, Chao Y, Cunningham D, Ferry DR, Smith NR, Frewer P, Ratnayake J, Stockman PK, Kilgour E, Landers D.

Ann Oncol. 2017 Jun 1;28(6):1316-1324. doi: 10.1093/annonc/mdx107.

PMID:
29177434
7.

SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer.

Soria JC, Fülöp A, Maciel C, Fischer JR, Girotto G, Lago S, Smit E, Ostoros G, Eberhardt WEE, Lishkovska P, Lovick S, Mariani G, McKeown A, Kilgour E, Smith P, Bowen K, Kohlmann A, Carlile DJ, Jänne PA.

Ann Oncol. 2017 Dec 1;28(12):3028-3036. doi: 10.1093/annonc/mdx628.

8.

A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers.

Paik PK, Shen R, Berger MF, Ferry D, Soria JC, Mathewson A, Rooney C, Smith NR, Cullberg M, Kilgour E, Landers D, Frewer P, Brooks N, André F.

Clin Cancer Res. 2017 Sep 15;23(18):5366-5373. doi: 10.1158/1078-0432.CCR-17-0645. Epub 2017 Jun 14.

9.

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.

Jänne PA, van den Heuvel MM, Barlesi F, Cobo M, Mazieres J, Crinò L, Orlov S, Blackhall F, Wolf J, Garrido P, Poltoratskiy A, Mariani G, Ghiorghiu D, Kilgour E, Smith P, Kohlmann A, Carlile DJ, Lawrence D, Bowen K, Vansteenkiste J.

JAMA. 2017 May 9;317(18):1844-1853. doi: 10.1001/jama.2017.3438.

10.

Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547.

Delpuech O, Rooney C, Mooney L, Baker D, Shaw R, Dymond M, Wang D, Zhang P, Cross S, Veldman-Jones M, Wilson J, Davies BR, Dry JR, Kilgour E, Smith PD.

Mol Cancer Ther. 2016 Nov;15(11):2802-2813. Epub 2016 Aug 22.

11.

High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.

Pearson A, Smyth E, Babina IS, Herrera-Abreu MT, Tarazona N, Peckitt C, Kilgour E, Smith NR, Geh C, Rooney C, Cutts R, Campbell J, Ning J, Fenwick K, Swain A, Brown G, Chua S, Thomas A, Johnston SRD, Ajaz M, Sumpter K, Gillbanks A, Watkins D, Chau I, Popat S, Cunningham D, Turner NC.

Cancer Discov. 2016 Aug;6(8):838-851. doi: 10.1158/2159-8290.CD-15-1246. Epub 2016 May 13.

12.

Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon.

Rooney C, Geh C, Williams V, Heuckmann JM, Menon R, Schneider P, Al-Kadhimi K, Dymond M, Smith NR, Baker D, French T, Smith PD, Harrington EA, Barrett JC, Kilgour E.

PLoS One. 2016 Feb 23;11(2):e0149628. doi: 10.1371/journal.pone.0149628. eCollection 2016.

13.

Complexity of FGFR signalling in metastatic urothelial cancer.

Rodriguez-Vida A, Saggese M, Hughes S, Rudman S, Chowdhury S, Smith NR, Lawrence P, Rooney C, Dougherty B, Landers D, Kilgour E, Arkenau HT.

J Hematol Oncol. 2015 Oct 24;8:119. doi: 10.1186/s13045-015-0221-6.

14.

Healing or harming? Healthcare provider interactions with injured workers and insurers in workers' compensation systems.

Kilgour E, Kosny A, McKenzie D, Collie A.

J Occup Rehabil. 2015 Mar;25(1):220-39. doi: 10.1007/s10926-014-9521-x. Review.

PMID:
24871375
15.

Interactions between injured workers and insurers in workers' compensation systems: a systematic review of qualitative research literature.

Kilgour E, Kosny A, McKenzie D, Collie A.

J Occup Rehabil. 2015 Mar;25(1):160-81. doi: 10.1007/s10926-014-9513-x. Review.

PMID:
24832892
16.

Screening haematology patients for carbapenem-resistant Klebsiella pneumoniae.

Inverarity D, Kilgour E, Dunn C, Thomas L, Fox R, Mitchell L, Paterson P.

J Infect Prev. 2014 Mar;15(2):50-56. doi: 10.1177/1757177413507120. Epub 2013 Oct 14.

17.

FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study.

Su X, Zhan P, Gavine PR, Morgan S, Womack C, Ni X, Shen D, Bang YJ, Im SA, Ho Kim W, Jung EJ, Grabsch HI, Kilgour E.

Br J Cancer. 2014 Feb 18;110(4):967-75. doi: 10.1038/bjc.2013.802. Epub 2014 Jan 23.

18.

Targeting non-small cell lung cancer cells by dual inhibition of the insulin receptor and the insulin-like growth factor-1 receptor.

Vincent EE, Elder DJ, Curwen J, Kilgour E, Hers I, Tavaré JM.

PLoS One. 2013 Jun 24;8(6):e66963. doi: 10.1371/journal.pone.0066963. Print 2013.

19.

FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.

Xie L, Su X, Zhang L, Yin X, Tang L, Zhang X, Xu Y, Gao Z, Liu K, Zhou M, Gao B, Shen D, Zhang L, Ji J, Gavine PR, Zhang J, Kilgour E, Zhang X, Ji Q.

Clin Cancer Res. 2013 May 1;19(9):2572-83. doi: 10.1158/1078-0432.CCR-12-3898. Epub 2013 Mar 14.

20.

Novel acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with reduced acyl glucuronide liability: the discovery of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid (AZD8329).

Scott JS, deSchoolmeester J, Kilgour E, Mayers RM, Packer MJ, Hargreaves D, Gerhardt S, Ogg DJ, Rees A, Selmi N, Stocker A, Swales JG, Whittamore PR.

J Med Chem. 2012 Nov 26;55(22):10136-47. doi: 10.1021/jm301252n. Epub 2012 Nov 7.

PMID:
23088558
21.

Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.

Zhang J, Zhang L, Su X, Li M, Xie L, Malchers F, Fan S, Yin X, Xu Y, Liu K, Dong Z, Zhu G, Qian Z, Tang L, Schöttle J, Zhan P, Ji Q, Kilgour E, Smith PD, Brooks AN, Thomas RK, Gavine PR.

Clin Cancer Res. 2012 Dec 15;18(24):6658-67. doi: 10.1158/1078-0432.CCR-12-2694. Epub 2012 Oct 18. Erratum in: Clin Cancer Res. 2013 Jul 1;19(13):3714. Schöttle, Jakob [added].

22.

Discovery of a potent, selective, and orally bioavailable acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor: discovery of 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic acid (AZD4017).

Scott JS, Bowker SS, Deschoolmeester J, Gerhardt S, Hargreaves D, Kilgour E, Lloyd A, Mayers RM, McCoull W, Newcombe NJ, Ogg D, Packer MJ, Rees A, Revill J, Schofield P, Selmi N, Swales JG, Whittamore PR.

J Med Chem. 2012 Jun 28;55(12):5951-64. doi: 10.1021/jm300592r. Epub 2012 Jun 19.

PMID:
22691057
23.

Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer.

Brooks AN, Kilgour E, Smith PD.

Clin Cancer Res. 2012 Apr 1;18(7):1855-62. doi: 10.1158/1078-0432.CCR-11-0699. Epub 2012 Mar 2. Review.

24.

AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.

Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S, Rooney C, Coleman T, Baker D, Mellor MJ, Brooks AN, Klinowska T.

Cancer Res. 2012 Apr 15;72(8):2045-56. doi: 10.1158/0008-5472.CAN-11-3034. Epub 2012 Feb 27.

25.

PDH kinase inhibitors: a novel therapy for Type II diabetes?

Mayers RM, Leighton B, Kilgour E.

Biochem Soc Trans. 2005 Apr;33(Pt 2):367-70. Review.

PMID:
15787608
26.

Mucociliary function deteriorates in the clinical range of inspired air temperature and humidity.

Kilgour E, Rankin N, Ryan S, Pack R.

Intensive Care Med. 2004 Jul;30(7):1491-4. Epub 2004 Mar 16.

PMID:
15024566
27.

AZD7545 is a selective inhibitor of pyruvate dehydrogenase kinase 2.

Morrell JA, Orme J, Butlin RJ, Roche TE, Mayers RM, Kilgour E.

Biochem Soc Trans. 2003 Dec;31(Pt 6):1168-70.

PMID:
14641019
28.

AZD7545, a novel inhibitor of pyruvate dehydrogenase kinase 2 (PDHK2), activates pyruvate dehydrogenase in vivo and improves blood glucose control in obese (fa/fa) Zucker rats.

Mayers RM, Butlin RJ, Kilgour E, Leighton B, Martin D, Myatt J, Orme JP, Holloway BR.

Biochem Soc Trans. 2003 Dec;31(Pt 6):1165-7. Review.

PMID:
14641018
29.

Identification of centaurin-alpha2: a phosphatidylinositide-binding protein present in fat, heart and skeletal muscle.

Whitley P, Gibbard AM, Koumanov F, Oldfield S, Kilgour EE, Prestwich GD, Holman GD.

Eur J Cell Biol. 2002 Apr;81(4):222-30.

PMID:
12018390
31.

Regulation of the GTP-binding protein-based antilipolytic system of sheep adipocytes by growth hormone.

Doris RA, Kilgour E, Houslay MD, Vernon RG.

J Endocrinol. 1998 Sep;158(3):295-303.

PMID:
9846158
32.
33.

Protein kinase C isoforms play differential roles in the regulation of adipocyte differentiation.

Fleming I, MacKenzie SJ, Vernon RG, Anderson NG, Houslay MD, Kilgour E.

Biochem J. 1998 Aug 1;333 ( Pt 3):719-27.

34.

Antisense technology reveals distinct roles for protein kinase C isoforms during 3T3-F442A preadipocyte differentiation.

Fleming IM, MacKenzie SJ, Houslay MD, Vernon RG, Kilgour E.

Biochem Soc Trans. 1997 Nov;25(4):S665. No abstract available.

PMID:
9450093
35.

Growth hormone and phorbol esters require specific protein kinase C isoforms to activate mitogen-activated protein kinases in 3T3-F442A cells.

MacKenzie S, Fleming I, Houslay MD, Anderson NG, Kilgour E.

Biochem J. 1997 May 15;324 ( Pt 1):159-65.

36.

Protein kinase C isoform expression during differentiation of 3T3-F442A preadipocytes.

Fleming IM, MacKenzie SJ, Houslay MD, Kilgour E.

Biochem Soc Trans. 1997 May;25(2):211S. No abstract available.

PMID:
9191255
37.

Effect of lactation on insulin signal transduction in sheep adipose tissue and skeletal muscle.

Wilson LA, Mills SE, Finley E, Kilgour E, Buttery PJ, Vernon RG.

J Endocrinol. 1996 Dec;151(3):469-80.

PMID:
8994392
38.

Prolactin modulates G-protein levels in the rat mammary gland.

Kilgour E.

Biochem Soc Trans. 1996 Aug;24(3):359S. No abstract available.

PMID:
8878903
39.

Cyclic AMP stimulates the phosphorylation and activation of p42 and p44 mitogen-activated protein kinases in 3T3-F442A preadipocytes.

Yarwood SJ, Kilgour E, Anderson NG.

Biochem Biophys Res Commun. 1996 Jul 25;224(3):734-9.

PMID:
8713115
41.

Chronic effects of somatotropin treatment on response of subcutaneous adipose tissue lipolysis to acutely acting factors in vivo and in vitro.

Doris RA, Thompson GE, Finley E, Kilgour E, Houslay MD, Vernon RG.

J Anim Sci. 1996 Mar;74(3):562-8.

PMID:
8707711
42.

Effects of lactation on the signal transduction systems regulating lipolysis in sheep subcutaneous and omental adipose tissue.

Vernon RG, Doris R, Finley E, Houslay MD, Kilgour E, Lindsay-Watt S.

Biochem J. 1995 May 15;308 ( Pt 1):291-6.

43.

Differential effects of wortmannin on growth hormone dependent signalling pathways in 3T3-F442A cells.

Anderson NG, Kilgour E.

Biochem Soc Trans. 1995 May;23(2):197S. No abstract available.

PMID:
7545604
44.

Cyclic AMP modulates adipogenesis in 3T3-F442A cells.

Yarwood SJ, Anderson NG, Kilgour E.

Biochem Soc Trans. 1995 May;23(2):175S. No abstract available.

PMID:
7545598
45.

Divergent regulation of rat adipocyte GLUT1 and GLUT4 glucose transporters by GH.

Kilgour E, Baldwin SA, Flint DJ.

J Endocrinol. 1995 Apr;145(1):27-33.

PMID:
7798027
46.

Modulation of adenosine signalling in sheep adipose tissue by growth hormone.

Doris R, Kilgour E, Houslay MD, Thompson GE, Vernon RG.

Biochem Soc Trans. 1995 Feb;23(1):16S. No abstract available.

PMID:
7758719
47.

Growth hormone induces the tyrosine phosphorylation and nuclear accumulation of components of the ISGF3 transcription factor complex.

Kilgour E, Anderson NG.

FEBS Lett. 1994 May 2;343(3):205-7. Erratum in: FEBS Lett 1994 Jul 25;349(1):161.

48.
49.

Growth hormone suppresses the expression of Gi2 in rat adipocytes.

Doris R, Vernon RG, Houslay MD, Kilgour E.

Biochem Soc Trans. 1993 Nov;21(4):432S. No abstract available.

PMID:
8132003
50.

Growth hormone decreases the amount of glucose transporter proteins in rat adipocyte plasma membranes.

Kilgour E, Baldwin SA, Flint DJ.

Biochem Soc Trans. 1993 Nov;21(4):429S. No abstract available.

PMID:
8132000

Supplemental Content

Loading ...
Support Center